ArticleBlood2021
Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
Abstract readLetter
In one paragraph
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- T cell lymphomas: cancers of aberrant immune synapse signalling.Nature reviews. Immunology · 2026Review
- Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma With Unusually Long Clinical Course.Journal of cutaneous pathology · 2026Article
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib.Blood advances · 2025Article
- Single-cell RNA sequencing comparison of CD4+, CD8+ and T-cell receptor γδ+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes.The British journal of dermatology · 2025Article
- Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).Current hematologic malignancy reports · 2025Review
- Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas.Hematology. American Society of Hematology. Education Program · 2024Review
- Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma with aberrant CD56 expression: a rare case report.Postepy dermatologii i alergologii · 2024Article
- JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature.Cancers · 2024Review
- Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.Frontiers in oncology · 2024Review
- Review
- Molecular techniques drive cutting edge advancements in management of cutaneous T cell lymphoma.Frontiers in immunology · 2023Review
- Tyrosine kinases in nodal peripheral T-cell lymphomas.Frontiers in oncology · 2023Review
- Review
- Advances in the understanding and treatment of Cutaneous T-cell Lymphoma.Frontiers in oncology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
23 authors.
Katie LeeDepartment of Dermatology and.ORCID 0000-0002-9919-4962
Mark G EvansDepartment of Pathology, Brigham and Women's Hospital and.ORCID 0000-0001-9358-9843
Lei YangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Spencer NgDepartment of Dermatology and.ORCID 0000-0002-1251-4514
Caroline SnowdenDepartment of Dermatology and.
Michael KhodadoustDivision of Oncology, Department of Medicine.ORCID 0000-0001-9061-7351
Ryanne A BrownDepartment of Dermatology and.ORCID 0000-0001-9099-7227
Nicholas A TrumDepartment of Dermatology, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-3256-4340
Christiane QuerfeldDepartment of Dermatology, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0001-9698-5809
Linda T DoanDepartment of Dermatology, University of California, Irvine, Irvine, CA.
Jinming SongDepartment of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
Hailing ZhangDepartment of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
Alejandro A GruDepartment of Pathology, University of Virginia, Charlottesville, VA.
Gary S WoodDepartment of Dermatology, University of Wisconsin, Madison, WI.
David A WadaDepartment of Dermatology and.
Vignesh ShanmugamDepartment of Pathology, Brigham and Women's Hospital and.
Paul L HaunPenn Cutaneous Lymphoma Program, Department of Dermatology, Perelman Center for Advanced Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Jon C AsterDepartment of Pathology, Brigham and Women's Hospital and.
Lyn M DuncanDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Joan GuitartDepartment of Dermatology and.
David M WeinstockDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-8724-3907
Valentina NardiDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Jaehyuk ChoiDepartment of Dermatology and.ORCID 0000-0003-2379-2226
Funding
Targeting oncogenic TCR signaling in PTCLP01CA233412 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2019 to 2023
$8.7MNorthwestern University Skin Disease Research Center Resource-based CenterP30AR075049 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI I. Caroline Le Poole · 2019 to 2026
$6.6MTargeting High-Risk Lymphoid NeoplasmsR35CA231958 · NCI · DANA-FARBER CANCER INST · PI WEINSTOCK, DAVID MARC · 2019 to 2021
$2.9MSkin Diseases Research Center at the University of WisconsinP30AR066524 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI LONGLEY, B JACK · 2014 to 2018
$2.6MIdentifying Mechanisms Governing T Cell DiversityDP2AI136599 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHOI, JAEHYUK · 2017 to 2017
$2.4MNCI NIH HHS P01 CA233412NCI NIH HHS R35 CA231958NIAID NIH HHS DP2 AI136599NIAMS NIH HHS P30 AR066524NIAMS NIH HHS P30 AR075049
Abstract
PubMed holds no abstract for this paper.
Indexed as
Signal TransductionAntineoplastic AgentsHumansJanus KinasesLymphoma, T-CellMolecular Targeted TherapyMutationSTAT Transcription FactorsAntineoplastic AgentsJanus KinasesSTAT Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.